EBCC12: Conference postponed until 30 Sept – 2 October 2020, in Barcelona Spain

On behalf of the 12th European Breast Cancer Conference (EBCC-12) Organising Committee, we would like to inform you that in view of the spread of coronavirus (COVID-19), and the stipulation from the Spanish Healthcare Ministry that Spanish healthcare workers should not attend national or international conferences, the committee has taken the decision to postpone the conference, which was due to start on Wednesday 18 March in Barcelona, Spain. It will now take place from 30 September to 2 October 2020 at the same venue in Barcelona.

We feel a responsibility towards the 2,500 healthcare workers expected to attend EBCC-12 and our primary concern is for the health and welfare of all our participants and staff, as well as the wider community.

We also believe that it is our collective responsibility to do what we can to minimise the risk of COVID-19 spreading further and to reduce the numbers of people travelling between countries at the present time.

As registered delegates, your registration will be automatically transferred to the new date. Please contact the conference secretariat if you find you are unable to attend in September. In addition, registrations will remain open at the regular rate until 24 August 2020. The conference secretariat will refund the difference between the regular and the late rate to any participant who has paid the late registration fee so far.

All abstracts that have been accepted for presentation to date will remain in the programme unless the presenters notify us that they wish to withdraw. However, abstract submission will reopen on 11 May 2020 until 7 August 2020. There will also be an opportunity to submit late breaking abstracts from 7 to 11 September 2020.

Exhibitors and sponsors will be contacted directly by the EBCC-12 Secretariat.

This is the only truly multidisciplinary conference in Europe that involves all the major players in breast cancer, facilitating essential interaction and communication between scientists, clinicians and patient representatives. We hope you will be able to attend in September and we look forward to seeing all our many friends and colleagues then.

The organising committee is continuing to monitor the situation and will provide further updates when necessary.

For any questions, please contact the EBCC secretariat:

Yours sincerely

Nadia Harbeck, Conference Chair
Tanja Spanic, Conference Co Chair
Javier Cortes, Local Conference Chair

Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC